Takeda Uses AcuraStem Deal To Bolster Neuro Pipeline, Move Into ALS

 
• By Joseph Haas

Deal Snapshot: Looking to add to its neuroscience pipeline, Takeda acquires rights to the antisense candidate AS-202 from AcuraStem for development as a potential amyotrophic lateral sclerosis therapy.

Takeda
Takeda will pursue ALS therapy under licensing pact with AcuraStem • Source: Shutterstock

More from Deals

More from Business